阿帕替尼治疗肺癌的研究进展  

Progress of apatinib in treatment of lung cancer

作　　者：刘雪微 周红凤[1] Liu Xuewei;Zhou Hongfeng(Department of Head and Neck Genitourinary Medicine,Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院头颈泌尿生殖内科,哈尔滨150081

出　　处：《肿瘤研究与临床》2022年第7期551-554,共4页Cancer Research and Clinic

基　　金：吴阶平医学基金会(320.6750.16072)。

摘　　要：肺癌是最常见的恶性肿瘤。阿帕替尼作为国内自主研发的第一代口服小分子酪氨酸激酶抑制剂,可高度选择性地阻断多种信号通路,通过抑制肿瘤血管生成发挥抗肿瘤作用,且不良反应安全可控。越来越多的研究表明阿帕替尼可用于晚期非小细胞肺癌患者的二线及以上治疗。文章将对阿帕替尼治疗肺癌的作用机制及临床研究进行综述。Lung cancer is the most common malignant tumor.As the first-generation oral small-molecule tyrosine kinase inhibitor independently developed in China,apatinib can block many kinds of signaling pathways with high selectivity,and play an anti-tumor effect by inhibiting tumor angiogenesis,and the adverse reactions are controllable.More and more studies have shown that apatinib can be used for the second-line and beyond treatment of patients with advanced non-small cell lung cancer.This article reviews the mechanisms and clinical studies of apatinib in treatment of lung cancer.

关 键 词：肺肿瘤 阿帕替尼 不良反应 预后 

分 类 号：R734.2[医药卫生—肿瘤]